Cargando…

Combinatorial fedratinib and venetoclax treatment is effective on human B cell acute lymphoblastic leukemia with high Flt3 expression

Treatment of relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) remains a challenge, particularly in patients who do not respond to traditional chemotherapy or immunotherapy. The objective of this study was to assess the efficacy of fedratinib, a semi selective JAK2 inhibitor and veneto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinella, Sean P, Bell, Haley C, Turicek, David P, Shi, Lei, Hoang, Nguyet-Minh, Rui, Lixin, Hess, Nicholas J, Capitini, Christian M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274796/ https://www.ncbi.nlm.nih.gov/pubmed/37333339 http://dx.doi.org/10.1101/2023.06.07.544058

Ejemplares similares

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
por: Aumann, Shlomzion, et al.
Publicado: (2022)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia
por: Frikha, Rim, et al.
Publicado: (2022)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia
por: Alkhayat, Nawaf, et al.
Publicado: (2017)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
por: Zhang, Lei-Si, et al.
Publicado: (2022)

Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation
por: Lázaro-Navarro, Juan, et al.
Publicado: (2021)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
por: Loftus, Joseph P., et al.
Publicado: (2020)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax
por: Fidyt, Klaudyna, et al.
Publicado: (2022)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
por: Chen, Yizhe, et al.
Publicado: (2022)

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2022)

PB1736: CLINICAL ANALYSIS OF VENETOCLAX-BASED IN THE TREATMENT OF ADULT RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Jing, et al.
Publicado: (2023)

Salvage treatment in IDH1 mutated acute lymphoblastic leukemia with venetoclax plus methotrexate and pegaspargase: A case report
por: Li, Dan, et al.
Publicado: (2023)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

P408: COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX
por: Renders, Simon, et al.
Publicado: (2023)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Survey of Activated FLT3 Signaling in Leukemia
por: Gu, Ting-lei, et al.
Publicado: (2011)

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology
por: Hess, Nicholas J., et al.
Publicado: (2023)

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
por: Milnerowicz, Szymon, et al.
Publicado: (2023)

Association between FLT3-ITD and additional chromosomal abnormalities in the prognosis of acute promyelocytic leukemia
por: Vu, Minh Phuong, et al.
Publicado: (2022)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
por: Jeyaraju, Danny, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pn8ar9kqcpi66s5brligf4tvgg